Advertisement
Canada markets close in 1 hour 47 minutes

  • S&P/TSX

    21,874.32
    -137.40 (-0.62%)
     

  • S&P 500

    5,070.78
    +0.23 (+0.00%)
     

  • DOW

    38,475.29
    -28.40 (-0.07%)
     

  • CAD/USD

    0.7297
    -0.0023 (-0.32%)
     

  • CRUDE OIL

    82.53
    -0.83 (-1.00%)
     

  • Bitcoin CAD

    88,741.80
    -2,768.52 (-3.03%)
     

  • CMC Crypto 200

    1,401.38
    -22.72 (-1.60%)
     

  • GOLD FUTURES

    2,336.70
    -5.40 (-0.23%)
     

  • RUSSELL 2000

    1,995.74
    -6.91 (-0.34%)
     

  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     

  • NASDAQ

    15,714.14
    +17.50 (+0.11%)
     

  • VOLATILITY

    15.69
    0.00 (0.00%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Investors focused on the Medical space have likely heard of DexCom (DXCM), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

DexCom is one of 898 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. DXCM is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 30.75% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

ADVERTISEMENT

Based on the latest available data, DXCM has gained about 20.22% so far this year. At the same time, Medical stocks have lost an average of 14.43%. This shows that DexCom is outperforming its peers so far this year.

Looking more specifically, DXCM belongs to the Medical - Instruments industry, a group that includes 96 individual stocks and currently sits at #41 in the Zacks Industry Rank.

Investors with an interest in Medical stocks should continue to track DXCM. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DexCom, Inc. (DXCM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research